Construction and characterization of a live attenuated vaccine candidate against Shigella dysenteriae type 1

Infection and Immunity

Volumn 65, Issue 6, 1997, Pages 2112-2118

  Klee, Silke R ^a   Tzschaschel, Barbara D ^a   Fält, Inger ^b   Kärnell, Anders ^b   Lindberg, Alf A ^b   Timmis, Kenneth N ^a   Guzmán, Carlos A ^a  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

SHIGELLA VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; BACTERIAL VIRULENCE; CELL SURVIVAL; CONTROLLED STUDY; GENETIC RECOMBINATION; IMMUNIZATION; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTECTION; SHIGELLA DYSENTERIAE; SHIGELLOSIS; TRANSPOSON; VACCINE PRODUCTION;

EID: 0030986852     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.65.6.2112-2118.1997     Document Type: Article

References (67)

1. Arnon, R., I. Harari, and G. Keusch. 1990. Vaccines against Shigella infections. III Synthetic peptide toxoid vaccines against Shiga dysentery, p. 688-697. In G. C. Woodrow and M. M. Levine (ed.), New generation vaccines. Marcel Dekker, New York, N.Y.
2. Attridge, S. R., D. Daniels, J. K. Morona, and R. Morona. 1990. Surface coexpression of Vibrio cholerae and Salmonella typhi O-antigens on Ty21a clone EX210. Microb. Pathog. 8:177-188.
3. Baron, L. S., D. J. Kopecko, S. B. Formal, R. Seid, P. Guerry, and C. Powell. 1987. Introduction of Shigella flexneri 2a type and group antigen genes into oral typhoid vaccine strain Salmonella typhi Ty21a. Infect. Immun. 55:2797-2801.
4. Bennish, M. L., J. R. Harris, B. J. Wojtyniak, and M. Struelens. 1990. Death in shigellosis: incidence and risk factors in hospitalized patients. J. Infect. Dis. 161:500-506.
5. 4a.Brahmbhatt, H. N. Unpublished data.
6. Chen, C. M., T. K. Misra, S. Silver, and B. P. Rosen. 1986. Nucleotide sequence of the structural genes for an anion pump. The plasmid-encoded arsenical resistance operon. J. Biol. Chem. 261:15030-15038.
7. Chu, C., B. Liu, D. Watson, S. Szu, D. Bryla, J. Shiloach, R. Schneerson, and J. B. Robbins. 1991. Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid. Infect. Immun. 59:4450-4458.
8. q/Ptrp-lac plasmids and transposons that confer conditional phenotypes. Gene 123:17-24.
9. DuPont, H. L., M. M. Levine, R. B. Hornick, and S. B. Formal. 1989. Inoculum size in shigellosis and implications for expected mode of transmission. J. Infect. Dis. 159:1126-1128.
10. Fält, I. C., E. K. H. Schweda, S. Klee, M. Singh, E. Floderus, K. N. Timmis, and A. A. Lindberg. 1995. Expression of Shigella dysenteriae type 1 O-antigenic polysaccharide by hybrid Shigella flexneri aroD vaccine candidates and different S. flexneri serotypes. J. Bacteriol. 177:5310-5315.
11. - mutant of Shigella dysenteriae 1. Infect. Immun. 56:3099-3109.
12. Formal, S. B., L. S. Baron, D. J. Kopecko, O. Washington, C. Powell, and C. A. Life. 1981. Construction of a potential bivalent vaccine strain: introduction of Shigella sonnei form I antigen genes into the galE Salmonella typhi Ty21a typhoid vaccine strain. Infect. Immun. 34:746-750.
13. Göhmann, S., P. A. Manning, C. A. Alpert, M. J. Walker, and K. N. Timmis. 1994. Lipopolysaccharide O-antigen biosynthesis in Shigella dysenteriae serotype 1: analysis of the plasmid-carried rfp determinant. Microb. Pathog. 16:53-64.
14. Goldberg, M. B., and P. J. Sansonetti. 1993. Shigella subversion of the cellular cytoskeleton: a strategy for epithelial colonization. Infect. Immun. 61:4941-4946.
15. Hale, T. L., P. Guerry, R. C. Seid, Jr., C. Kapfer, M. E. Wingfield, C. B. Reaves, L. S. Baron, and S. B. Formal. 1984. Expression of lipopolysaccharide O antigen in Escherichia coli K-12 hybrids containing plasmid and chromosomal genes from Shigella dysenteriae 1. Infect. Immun. 46:470-475.
16. Halling, S. M., R. W. Simons, J. C. Way, R. B. Walsh, and N. Kleckner. 1982. DNA sequence organization of IS10-right of Tn10 and comparison with IS10-left. Proc. Natl. Acad. Sci. USA 79:2608-2612.
17. Hartman, A. B., C. J. Powell, C. L. Schultz, E. V. Oaks, and K. H. Eckels. 1991. Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains. Infect. Immun. 59:4075-4083.
18. Hartman, A. B., L. Van De Verg, H. H. Collins, D. B. Tang, N. O. Bendiuk, D. N. Taylor, and C. J. Powell. 1994. Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines. Infect. Immun. 62:412-420.
19. Herrero, M., V. de Lorenzo, and K. N. Timmis. 1990. Transposon vectors containing non-antibiotic resistance selection markers for cloning and stable chromosomal insertion of foreign genes in gram-negative bacteria. J. Bacteriol. 172:6557-6567.
20. Herrington, D. A., L. Van de Verg, S. B. Formal, T. L. Hale, B. D. Tall, S. J. Cryz, E. C. Tramont, and M. M. Levine. 1990. Studies on volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. Vaccine 8:353-357.
21. Hitchcock, P. J., and T. M. Brown. 1983. Morphological heterogeneity among Salmonella lipopolysaccharide chemotypes in silver-stained polyacrylamide gels. J. Bacteriol. 154:269-277.
22. Kado, C. I., and S.-T. Liu. 1981. Rapid procedure for detection and isolation of large and small plasmids. J. Bacteriol. 145:1365-1373.
23. Kadurugamuwa, J. L., M. Rohde, J. Wehland, and K. N. Timmis. 1991. Intercellular spread of Shigella flexneri through a monolayer mediated by membranous protrusions and associated with reorganization of the cytoskeletal protein vinculin. Infect. Immun. 59:3463-3471.
24. Kärnell, A., B. A. D. Stocker, S. Katakura, F. P. Reinholt, and A. A. Lindberg. 1992. Live oral auxotrophic Shigella flexneri SFL124 vaccine with a deleted aroD gene: characterization and monkey protection studies. Vaccine 10:389-394.
25. Kärnell, A., H. Sweiha, and A. A. Lindberg. 1992. Auxotrophic live oral Shigella flexneri vaccine protects monkeys against challenge with S. flexneri of different serotypes. Vaccine 10:167-174.
26. Katz, S. L. (ed.). 1986. New vaccine development. Diseases of importance in developing countries, vol. 2, p. 329-337. National Academy of Sciences Press, Washington, D.C.
27. Klena, J. D., R. S. Ashford II, and C. A. Schnaitman. 1992. Role of Escherichia coli K-12 rfa genes and the rfp gene of Shigella dysenteriae 1 in generation of lipopolysaccharide core heterogeneity and attachment of O antigen. J. Bacteriol. 174:7297-7307.
28. Kreuzer, K., C. Pratt, and A. Torriani. 1975. Genetic analysis of regulatory mutants of alkaline phosphatase of E. coli. Genetics 81:459-468.
29. Lesse, A. J., A. A. Campagnari, W. E. Bittner, and M. A. Apicella. 1990. Increased resolution of lipopolysaccharides and lipooligosaccharides utilizing tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis. J. Immunol. Methods 126:109-117.
30. Levine, M. M. 1982. Bacillary dysentery. Mechanisms and treatment. Med. Clin. North Am. 66:623-638.
31. Li, A., P. D. Cam, D. Islam, B. Minh, and A. A. Lindberg. 1994. Immune responses in Vietnamese children after a single dose of the auxotrophic, live Shigella flexneri Y vaccine strain SFL124. J. Infect. 28:11-23.
32. Li, A., A. Kärnell, P. T. Huan, P. D. Cam, N. B. Minh, L. N. Tam, N. P. Quy, D. D. Trach, K. Karlsson, G. Lindberg, and A. A. Lindberg. 1993. Safety and immunogenicity of the live oral auxotrophic Shigella flexneri SFL124 in adult Vietnamese volunteers. Vaccine 11:180-189.
33. Li, A., T. Pál, U. Forsum, and A. A. Lindberg. 1992. Safety and immunogenicity of the live oral auxotrophic Shigella flexneri SFL124 in volunteers. Vaccine 10:395-404.
34. Lindberg, A. A., A. Kärnell, T. Pál, H. Sweiha, K. Hultenby, and B. A. D. Stocker. 1990. Construction of an auxotrophic Shigella flexneri strain for use as a live vaccine. Microb. Pathog. 8:433-140.
35. Lindberg, A. A., and T. Pál. 1993. Strategies for development of potential candidate Shigella vaccines. Vaccine 11:168-179.
36. Lopez, E. L., M. Diaz, S. Grinstein, S. Devoto, F. Mendilaharzu, B. E. Murray, S. Ashkenazi, E. Rubeglio, M. Woloj, M. Vazquez, M. Turco, L. Pickering, and T. Cleary. 1984. Hemolytic uremic syndrome and diarrhea in Argentine children: the role of Shiga-like toxins. J. Infect. Dis. 160:469-475.
37. Mallett, C. P., L. Van de Verg, H. H. Collins, and T. L. Hale. 1993. Evaluation of Shigella vaccine safety and efficacy in an intranasally challenged mouse model. Vaccine 11:190-196.
38. Mason, P. R., K. J. Nathoo, M. Wellington, and E. Mason. 1995. Antimicrobial susceptibilities of Shigella dysenteriae type 1 isolated in Zimbabwe-implications for the management of dysentery. Cent. Afr. J. Med. 41:132-137.
39. Meitert, T., E. Pencu, L. Ciudin, and M. Tonciu. 1984. Vaccine strain S. flexneri T32-Istrati. Studies in animals and in volunteers. Antidysentery immunoprophylaxis and immunotherapy by live vaccine Vadizen (S. flexneri T32-Istrati). Arch. Roum. Pathol. Exp. Microbiol. 43:251-278.
40. Mills, S. D., and K. N. Timmis. 1988, Genetics of O-antigen polysaccharide biosynthesis in Shigella and vaccine development. Bacteria, complement and the phagocytic cell. NATO ASI Ser. A H24:21-39.
41. Newland, J. W., T. L. Hale, and S. B. Formal. 1992. Genotypic and phenotypic characterization of an aroD deletion-attenuated Escherichia coli K12-Shigella flexneri hybrid vaccine expressing S. flexneri 2a somatic antigen. Vaccine 10:766-776.
42. Noriega, F. R., J. Y. Wang, G. Losonsky, D. R. Maneval, D. M. Hone, and M. M. Levine. 1994. Construction and characterization of attenuated ΔaroA ΔvirG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine. Infect. Immun. 62:5168-5172.
43. Oberhelman, R. A., D. J. Kopecko, E. Salazar-Lindo, E. Gotuzzo, J. M. Buysse, M. M. Venkatesan, A. Yi, C. Fernandez-Prado, M. Guzman, R. León-Barúa, and R. B. Sack. 1991. Prospective studies of systemic and mucosal immune responses in dysenteric patients to specific Shigella invasion plasmid antigens and lipopolysaccharides. Infect. Immun. 59:2341-2350.
44. Okada, N., C. Sasakawa, T. Tobe, M. Yamada, S. Nagai, K. A. Talukder, K. Komtsu, S. Kanegasaki, and M. Yoshikawa. 1991. Virulence-associated chromosomal loci of Shigella flexneri identified by random Tn5 insertion mutagenesis. Mol. Microbiol. 5:187-195.
45. Pal, S. C., P. G. Sengupta, D. Sen, S. K. Bhattacharya, and B. C. Deb. 1989. Epidemic shigellosis due to Shigella dysenteriae type 1 in south Asia. Indian J. Med. Res. 89:57-64.
46. Raqib, R., S. Tzipori, M. Islam, and A. A. Lindberg. 1993. Immune responses to Shigella dysenteriae 1 and Shigella flexneri lipopolysaccharide and polysaccharide antigens in Bangladeshi patients with shigellosis. Serodiagn. Immunother. Infect. Dis. 1:37-45.
47. Richards, E. 1987. Preparation of genomic DNA from bacteria. Miniprep of bacterial genomic DNA, p. 1-2. In F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (ed.). Current protocols in molecular biology. Unit 2.4.1. John Wiley & Sons, Inc., New York, N.Y.
48. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
49. Sandlin, R. C., K. A. Lampel, S. P. Keasler, M. B. Goldberg, A. L. Stolzer, and A. T. Maurelli. 1995. Avirulence of rough mutants of Shigella flexneri: requirement of O antigen for correct unipolar localization of IcsA in the bacterial outer membrane. Infect. Immun. 63:229-237.
50. Sansonetti, P. J., J. Arondel, A. Fontaine, H. d'Hauteville, and M. L. Bernardini. 1991. OmpB (osmo-regulation) and icsA (cell-to-cell spread) mutants of Shigella flexneri: vaccine candidates and probes to study the pathogenesis of shigellosis. Vaccine 9:416-422.
51. Sansonetti, P. J., D. J. Kopecko, and S. B. Formal. 1982. Involvement of a plasmid in the invasive ability of Shigella flexneri. Infect. Immun. 35:852-860.
52. Sasakawa, C., K. Kamata, T. Sakai, S. Y. Murayamn, S. Makino, and M. Yoshikawa. 1986. Molecular alteration of the 140-megadalton plasmid associated with loss of virulence and Congo red binding activity in Shigella flexneri. Infect. Immun. 51:470-475.
53. Seid, R. C., D. J. Kopecko, J. C. Sadoff, H. Schneider, L. S. Baron, and S. B. Formal. 1984. Unusual lipopolysaccharide antigens of a Salmonella typhi oral vaccine strain expressing the Shigella sonnei form I antigen. J. Biol. Chem. 259:9028-9034.
54. Serény, B. 1957. Experimental keratoconjunctivitis shigellosa. Acta Microbiol. Acad. Sci. Hung. 4:367-376.
55. Sturm, S., B. Jann, K. Jann, P. Fortnagel, and K. N. Timmis. 1986. Genetic and biochemical analysis of Shigella dysenteriae 1 O antigen polysaccharide rfb gene cluster. Microb. Pathog. 1:307-324.
56. Sturm, S., and K. N. Timmis. 1986. Cloning of the rfb gene region of Shigella dysenteriae 1 and construction of an rfb-rfp gene cassette for the development of lipopolysaccharide-based live anti-dysentery vaccines. Microb. Pathog. 1:289-297.
57. Taylor, D. N., L. Bodhidatta, J. E. Brown, P. Echeverria, C. Kunanusont, P. Naigowit, S. Hanchalay, A. Chatkaemorakot, and A. A. Lindberg. 1989. Introduction and spread of multi-resistant Shigella dysenteriae 1 in Thailand. Am. J. Trop. Med. Hyg. 40:77-85.
58. Taylor, D. N., A. C. Trofa, J. Sadoff, C. Chu, D. Bryla, J. Shiloach, D. Cohen, S. Ashkenazi, Y. Lerman, W. Egan, R. Schneerson, and J. B. Robbins, 1993. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1. Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids. Infect. Immun. 61:3678-3687.
59. Tsai, C. M., and C. E. Frasch. 1982. A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal. Biochem. 119:115-119.
60. Tzschaschel, R. D., S. R. Klee, V. de Lorenzo, K. N. Timmis, and C. A. Guzmán. 1996. Towards a vaccine candidate against Shigella dysenteriae 1: expression of the Shiga toxin B-subunit in an attenuated Shigella flexneri aroD carrier strain. Microb. Pathog. 21:277-288.
61. Verma, N. K., and A. A. Lindberg. 1991. Construction of aromatic dependent Shigella flexneri 2a live vaccine candidate strains: deletion mutations in the aroA and the aroD genes. Vaccine 9:6-9.
62. Viret, J. F., S. J. Cryz, A. B. Lang, and D. Favre. 1993. Molecular cloning and characterization of the genetic determinants that express the complete Shigella serotype D (Shigella sonnei) lipopolysaccharide in heterologous live attenuated vaccine strains. Mol. Microbiol. 7:239-252.
63. Watanabe, H., and K. N. Timmis. 1984. A small plasmid in Shigella dysenteriae 1 specifies one or more functions essential for O antigen production and bacterial virulence. Infect. Immun. 43:391-396.
64. Westphal, O., and K. Jann. 1965. Bacterial lipopolysaccharides: extraction with phenol-water and further applications of the procedure. Methods Carbohydr. Chem. 5:83-91.
65. Winsor, D. K., J. J. Mathewson, and H. L. DuPont. 1988. Comparison of serum and fecal antibody responses of patients with naturally acquired Shigella sound infection. J. Infect. Dis. 158:1108-1112.
66. World Health Organization. 1990. Programme for control of diarrhoeal diseases, seventh programme report, 1988-1989. Document WHO/CDD/90.34. World Health Organization, Geneva, Switzerland.
67. World Health Organization. 1995. Division of diarrhoeal and acute respiratory disease control, Interim report 1994. Document WHO/CDR/95.1. World Health Organization, Geneva, Switzerland.